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ABSTRACT
Treatment of infrabony pocket makes use of bone graft material demineralized freeze dried bone allograft (DFDBA) from 
different individuals which has undergone demineralization process and it is osteoinductive. Enhancement of growth 
factor was done by adding platelet rich fibrin (PRF) and platelet rich plasma (PRP). PRP is activated with an addition 
of calcium chloride (CaCl2) to form gel. The method used to apply the bone grafting material is open flap debridement 
(OFD). This research aimed to reveal the differences in the results of infrabony pocket treatment using PRF and PRP gel 
with an addition of DFDBA. The sample was taken from 20 infrabony pocket points divided into 2 groups, 10 infrabony 
pocket were treated with OFD+DFDBA+PRF and the other were treated with OFD+DFDBA+PRP gel. Pocket depth 
(PD) was measured on the baseline and the first and third month after treatment. Alveolar bone height was measured 
using cone beam computed tomography (CBCT) radiograph on the baseline to the third month after treatment. The 
results of this research showed that there was difference in the results of infrabony pocket treatment using PRF and PRP 
gel with an addition of DFDBA which could be observed from a reduction in PD from the baseline, month 1 and month 
3 as well as reduction in alveolar bone height from the baseline to month 3. This research concluded that infrabony 
pocket treatment PRF application yields better results than PRP gel application in terms of PD and alveolar bone height 
reduction. 
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INTRODUCTION
Periodontal pocket, also known as true pocket, is 
the main clinical symptom of periodontal diseases. 
Infrabony pocket is a pocket of which the base is 
more apical to the level of the adjacent alveolar 
bone, therefore the lateral pocket wall lies between 
the root surface and alveolar bone.1 The main 
purpose of periodontal disease treatment is for 
periodontal tissue regeneration as a result of 
infection, including alveolar bone, periodontal 
ligament and cementum. Treatment of periodontal 
disease protects and maintains the oral health of 
patients in order to continue to function optimally 
in terms of mastication, comfort and aesthetics.2 A 
number of treatments for periodontal diseases have 
been developed, the most often used technique is 
flap surgery.1
There are various materials used in periodontal 
treatment including guided tissue regeneration 
(GTR), graft material, application of growth factor, 
with an objective to stimulate periodontal tissue 
regeneration especially infrabony defect. PRF 
contains glycosaminoglycan (heparin, hyaluronic 
acid), transforming growth factor-β 1 (TGF β-1), 
platelet derived growth factors (PDGFs), insulin-
like growth factor 3 (IGF), interleukin-1β (IL-1β), 
interleukin 6 (IL-6), tumor necrosis factor a (TNFa), 
interleukin 4 (IL-4), and vascular endothelial growth 
factor (VEGF).3 
Platelet-rich plasma (PRP) is autologous 
platelet in plasma concentrated by centrifugation. 
PRP contains growth factor such as PDGF, TGF-β, 
and VEGF.4 PRP can be activated (usually by 
CaCl2 and/or thrombin) and applied over wound 




area. Growth factor will be released gradually when 
platelet gel is formed using CaCl2. CaCl2 activates 
and clots PRP by forming autogenous thrombin 
from prothrombin, resulting in the formation of a 
loose fibrin matrix which will release growth factor 
over 7 days.5 
Demineralized Freeze Dried Bone Allograft 
(DFDBA) is bone graft decalcified in hydrochloric acid 
then freeze dried, it can function as osteoinductor 
thus inducing new bone formation and stimulating 
mesenchymal cell maturation.6 Wound healing is 
a dynamic, continuous, overlapping process which 
consists of several phases, namely hemostasis, 
inflammation, differentiation, proliferation, migration 
of mesenchymal cells to wound area, angiogenesis, 
re-epithelialization, synthesis and regulation of 
collagen, vascular maturation or remodeling.7,8 
Bone healing occurs one month after bone graft 
is performed, and after three months it becomes 
obvious on a radiographic examination. Maturation 
of bone graft in laminar bone requires varied 
healing time, ranging from 3 to 6 months, and 
depends on various factors such as age, wound 
healing factor, size of wound, bone damage in the 
grafting area.8 Based on the above background, we 
were interested in conducting a research to reveal 
differences in results of infrabony pocket treatment 
with addition of PRF and PRP gel in DFDBA bone 
graft at periodontal clinic Prof. Soedomo UGM 
Dental Hospital.
MATERIALS AND METHODS
This was a quasi-experimental research. The 
inclusion criteria consisted of patients aged 21-60 
years old suffering from chronic periodontitis with 
pocket depth >5 mm and with damage to infrabony 
bone. They were willing to sign an informed 
consent. The exclusion criteria were smokers/
alcoholic drinkers, taking long-term drugs, unwilling 
to undergo a surgical procedure, unwilling to join 
the research until finished.
The samples in this study consisted of 20 
infrabony pocket points in patients with chronic 
periodontitis, divided into 2 treatment groups. Group 
A consisted of 10 infrabony pockets treated with OFD, 
DFDBA and PRF. Group B consisted of 10 infrabony 
pocket treated with Open Flap Debridement (OFD), 
DFDBA and PRP gel. Pocket depth (PD) was 
measured before the surgery (baseline), the first 
and third month after the surgery. Bone height was 
measured before the surgery (baseline) and in the 
3rd month after the surgery.
This research was conducted in the following 
stages, application for ethical clearance to the 
dental research ethics commission Faculty of 
Dentistry UGM No 001379/KKEP/FKG-UGM/
EC/2018, clinical examination, measurement of 
plaque index and initial phase therapy consisting of 
dental health education (DHE) as well as scaling 
and root planning, occlusion adjustment if there 
was occlusal trauma and splinting if there were 
shaking teeth with a mobility greater than 1 degree. 
Measurement and recording of plaque index (PI), 
initial data collection, and measurement of PD and 
bone height were done in the teeth to be treated. 
Extraoral CBCT was done to measure bone height.
PRF was made by taking 10 ml blood sample 
intravenously from patients using syringe, then 
transferred to a tube and centrifuged at 2700 
revolutions per minutes (rpm) for 12 minutes. The 
centrifugation resulted in three layers, i.e. the top 
most layer contained acellular plasma, the middle 
layer contained PRF, and the bottom most layer 
contained red blood cells, then PRF was segregated 
from the second layer.9
Preparation of Platelet-rich plasma was 
prepared one hour before surgery, by taking 9 ml 
blood from each of the subjects from their basilic 
vein to be put in a 10 ml tube containing 1 ml sodium 
citrate anticoagulant 3.8% and 9 ml blood. The first 
centrifugation was done at 2400 rpm for 10 minutes. 
The blood in the tube was separated into two layers, 
i.e. the bottom most layer containing red blood cells 
and the top most layer containing blood plasma and 
buffy coat or platelet pool. Aspiration of the top layer 
was done using a pipette then put in another tube, 
centrifuged at 3600 rpm for 15 minutes. Afterwards, 
the top layer was aspirated as much as 2/3 from the 
volume of the supernatant, while the remaining 1/3 
lower part contained platelets, a small amount of 
blood cells and plasma, named PRP.10
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PRP gel was prepared immediately before 
application. At the first stage, autologous thrombin 
was made by taking 4 ml autologous blood into a 
tube and left for ± 30 minutes until it coagulated. 
The tube was then centrifuged at 3600 rpm for 12 
minutes. The top most layer of the supernatant 
was collected as autologous thrombin. PRP gel 
was made by mixing 0.1 ml autologous thrombin 
with 0.03 ml CaCl2 10%. The ratio of PRP and 
autologous thrombin was 10:1.11
The anesthesia used for periodontal flap 
surgery was local anesthesia, injected after 
the surgical area was first disinfected. Vertical 
and sulcular full thickness flap incisions were 
performed. The flap was elevated and debridement 
was performed in bone defect by scaling root 
planning and curettage. Solution of 75 mg/ml 
tetracycline HCl was applied to the hard tissue for 
3 minutes, and rinsed using distilled water. DFDBA 
bone graft material was applied, combined with 
PRF and PRP gel on the surgical area, then the 
flap was returned and sutured with an uninterrupted 
vertical mattress suture technique, then covered 
with periodontal dressing. The patients were given 
amoxycilin antibiotics with a dose of 500 mg for 5 
days, analgesics and antiinflamatory drugs. They 
were asked to return for PD clinical parameter 
measurement, 1 month and 3 months after the 
surgery. The second X-ray image was taken 3 
months after the surgery. PD was measured using 
periodontal probe UNC 15. Alveolar bone height 
was measured using software on CBCT images in 
sagittal, longitudinal and axial sections.
The data from the results of this research were 
analyzed using SPSS IBM version 23.0. Normality 
test was performed to the results of pocket depth 
(PD) measurement according to the observation 
time within the same group using Shapiro-Wilk test, 
followed with non parametric test. The data of PD 
reduction among groups were analyzed using U 
Mann-Whitney test. 
Normality test was also performed to the 
analysis results of alveolar bone height using 
Shapiro-Wilk test, followed by parametric paired 
t-test. The data of bone height reduction among the 
groups was analyzed using independent t-test.
RESULTS
The data collected in this study were the results of 
clinical parameter measurement and radiological 
examination in the two groups of patients who 
suffered from chronic periodontitis with infrabony 
bone damage. The first group was treated with 
periodontal flap surgery with an addition of 
DFDBA and PRF, while the second group was 
treated with periodontal flap surgery with an addition 
of DFDBA and PRP gel. 
Table 1 indicates that the highest mean of PD 
was obtained by the group with OFD+DFDBA+PRF 
on the baseline with a mean and standard deviation 
of 6.70 ± 0.48 mm. The lowest mean of PD was 
found in the group with OFD+DFDBA+PRP gel in 
the third month with a mean and standard deviation 
of 2.50 ± 0.52 mm.
The data in Table 2 show that there was PD 
reduction in both groups with the highest reduction 
in the group with OFD+DFDBA+PRF from the 
baseline to the third month. The highest mean of PD 
reduction was in the group with OFD+DFDBA+PRF 
from the baseline to month 3, i.e. 4.20 ± 0.79 mm 
and the lowest reduction of PD was in month 1 to 
month 3 in the second group, i.e. 1.20 ± 0.79 mm.
Normality test with Shapiro-Wilk test and 
homogeneity test with Levene test were performed 
on the data distribution in each of the groups. Table 
3 below shows the results of the Shapiro-Wilk test 
on the data of PD reduction.
Table 1. Mean and standard deviation of pocket depth (PD) 




Baseline 10 6.70 ± 0.48 6.40 ± 0.51
Month 1 10 3.70 ± 0.67 4.20 ± 0.67
Month 3 10 2.50 ± 0.52 3.00 ± 0.81





Baseline – month 1 10 3.00 ± 0.81 2.20 ± 0.63
Baseline - month 3 10 4.20 ± 0.79 3.40 ± 0.84
Month 1- month 3 10 1.20 ± 0.79 3.00 ± 0.79




Table 3. Results of Shapiro-Wilk test on PD reduction
OFD+DFDBA Significance level Description
PRF month 0-1 0.035 Abnormal
PRF month 0-3 0.023 Abnormal
PRF month 1-3 0.004 Abnormal
PRP gel month 0-1 0.012 Abnormal
PRP gel month 0-3 0.172 Normal
PRP gel month 1-3 0.004 Abnormal
Table 4. Results of Mann Whitney test on PD reduction among 
observation time and treatment groups 
Mann whitney Significance level Description
Baseline - month 1 0.035 Significant
Baseline - month 3 0.046 Significant
Month 1 - month 3 1.000 Not significant
Table 5. Mean and standard deviation of alveolar bone height 
according to observation time and treatment groups
Time n
OFD+   DFDBA
PRF   PRP gel
Baseline 10 6.01 ± 1.57 6.11 ± 0.88
Month 3 10 3.96 ± 0.92 4.92 ± 0.63
This means that the data distribution in both 
groups was abnormal. Since the Shapiro-Wilk test 
resulted in abnormal data distribution, the statistical 
test was continued with non parametric Mann 
Whitney test
Table 4 shows the results of Mann Whitney 
test on PD reduction with a significance level of 
p<0.05, indicating there was statistically significant 
difference between the groups when measured 
from the baseline to month 1, baseline to month 
3, while the significance level of the measurement 
from month 1 to month 3 was p>0.05, meaning 
that there was no statistically significant difference 
between these groups.
Table 5 shows the that highest mean of bone 
height was found in the group of OFD+DFDBA+PRP 
gel in month 0 (baseline), is 6.11 ± 0.88 mm, while the 
lowest one was in the group of OFD+DFDBA+PRF 
in month 3, is 3.96 ± 0.92 mm. Table 6 shows that 
the highest bone height reduction was found in the 
group of OFD+DFDBA+PRF from the baseline to 
month 3, i.e. 2.05 ± 0.93 mm while the lowest 
reduction was in the group of OFD+DFDBA+PRP 
gel from the baseline to month 3, i.e. 1.19 ± 0.82 
mm.
The data distribution in each of the groups was 
tested using the Shapiro-Wilk normality test and 
Levene homogeneity test. Table 7 below presents 
the results of the Shapiro-Wilk normality test on the 
data of bone height reduction.
The Shapiro-Wilk normality test, as presented 
in Table 7, resulted in a significance level 
p>0.05 in the groups of OFD+DFDBA+PRF and 
OFD+DFDBA+PRP gel in month 0. This indicates 
that these groups had normal data distribution.
The homogeneity test in Table 8 resulted 
in a significance level of p>0.05 in the groups of 
OFD+DFDBA+PRF and OFD+DFDBA+PRP gel, 
so the data were homogeneous. These tests 
showed that the groups had normal data distribution 
and the data were homogeneous, thus followed 
by a statistical test in the form of parametric 
Independent t-test. Table 9 shows that coronal 
bone height reduction from the baseline to month 3 
had p<0.05, meaning that there was a statistically 
significant difference in the reduction of bone height 
in the baseline and in month 3 between the two 
treatment groups.
Table 6. Mean and standard deviation of alveolar bone height 
reduction according to treatment groups
Time n
OFD+   DFDBA
PRF PRP gel
Baseline- month 3 10 2.05 ± 0.93     1.19 ± 0.82







PRF month 0 - month 3 0.223 Normal
PRP gel month 0-3 0.177 Normal
Table 8. Results of homogenity test on alveolar bone height 
reduction 
Levene statistic Significance level (p) Description
0.669 Homogeneous
Table 9. Results of independent t-test on alveolar bone height 
reduction among treatment groups
Significance level Description
Baseline- month 3 0.042 Significant
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Figure 1. Images of alveolar bone height (A) baseline (B) 
month 3 treatment with PRF
DISCUSSION
PD reduction from the baseline to month 1 and 
from the baseline to month 3 showed a significant 
difference between the two treatment groups. The 
reduction in the group of OFD+DFDBA+PRF from 
the baseline to month 3 was greater than that of 
OFD+DFDBA+ PRP gel indicating that the group 
of OFD+DFDBA+PRF underwent angiogenesis, 
allowing regeneration process to take place 
optimally. the Growth factor contained in PRF is 
capable of increasing the formation of cementum 
and proliferation of periodontal ligament fibroblasts.9 
Receptors of growth factor are found in periodontal 
ligament which will activate fibroblasts. PRP gel 
produces less IGF-1 compared to PRF. The growth 
factors contained in PRP play a role as a biological 
mediator which affects proliferation, differentiation, 
migration and attachment of periodontal progenitor 
cells.11 Unfortunately the process of making 
PRP requires additional anticoagulants in large 
quantities and also bovine-derived thrombin 
which functions to convert fibrinogen to fibrin. The 
addition of thrombin from bovine makes PRP not 
purely autologous so that side effects are obtained 
in the form of antibodies to factor V, XI and thrombin 
which results in coagulopathy.12
The results of reduction from month 1 to month 
3 showed no significant difference between the two 
treatment groups, meaning that in general the two 
treatment groups underwent the same regeneration 
process. Wound healing immediately took place 
over time after the treatment was given and 
started from hemostasis, inflammatory, proliferative 
and remodeling phases.13 In hemostasis phase, 
space between flap and bone surface is filled 
with blood clots consisting of fibrin threads with 
large amounts of polymorphonuclear leukocytes, 
erythrocytes, and debris from damaged cells as 
well as capillaries at the edges of the wound. After 
the hemostasis phase, wound healing enters the 
inflammatory phase which reaches its peak on 
day 2-3, proliferative phase which reaches its peak 
in week 2-3, then remodeling phase which starts 
during the peak of proliferative phase, i.e. week 3 
or day 21, and the bone regeneration process takes 
place ± 1-3 months; one of the success parameters 
of periodontitis treatment can be seen from PD 
reduction.1,14 
The data showed that the highest mean of 
alveolar bone height reduction was found in the 
group of OFD+DFDBA+PRF from the baseline to 
month 3, while the lowest mean of bone height 
reduction was in the group of OFD+DFDBA+PRP 
gel from the baseline to month 3. A high alveolar 
bone height reduction results in lower alveolar bone 
height, indicating bone repair. Increased alveolar 
bone repair shows periodontal tissue regeneration 
which can be seen in X-ray images in the form of a 
radiopaque area in alveolar bone.15
Difference in bone height in the group of 
ODF+DFDBA+PRF and that of OFD+DFDBA+PRP 
gel shows a significant result, meaning that there 
was a significant difference between the two groups 
from the baseline to month 3. Activation of platelet 
rich plasma in this study used CaCl2 which activated 
the growth factors contained in PRP. CaCl2 added 
after the second centrifugation resulted in a more 
gel-like PRP consistency, making it easily applied 
to bone defect or damage. Addition of CaCl2 could 
stimulate the release of platelet growth factor 
and increase the proliferation and migration of 
osteoblasts. The use of PRF will be more effective 
because PRF clots form a strong 3-dimensional 
fibrin matrix, and unlike PRP gel, fibrin matrix will 
be re-formed gradually with a pattern similar to that 
of natural blood clot matrix formation.16
CONCLUSION
This study concluded that there are differences 
in the results of infrabony pocket treatment using 
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platelet rich fibrin and platelet rich plasma gel with 
an addition of demineralized freeze dried bone 
allograft. This is evident from the fact that pocket 
depth reduction and alveolar bone height repair 
due to the application of PRF are greater than that 
of PRP gel. Based on the results of this study, it 
is recommended that a research with a longer 
observation time be conducted in order to see the 
stability of alveolar bone. In addition, it is necessary 
to perform patients’ blood tests prior to taking blood 
sample for the making of PRF and PRP gel.
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